Business Context and Reporting Period
This Form 6-K filing by Therapix Biosciences Ltd. (not Scisparc Ltd.) covers the month of January 2018, with the report dated January 16, 2018. The registrant is a foreign private issuer based in Givatayim, Israel, focused on developing treatments for neurological disorders.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current event update regarding regulatory status rather than a financial statement.
Material Changes and Regulatory Update
The primary material event concerns the U.S. Food and Drug Administration (FDA) response to the company's request for Orphan Drug Designation for THX-110 (also referred to as THX-TS01 in the header) for the treatment of Tourette Syndrome (TS).
- Timeline: The initial request was submitted in June 2016. The company responded to an FDA letter dated September 29, 2016, on September 27, 2017. The FDA's final response was received on December 26, 2017.
- FDA Decision: The FDA accepted the scientific rationale for treating TS with THX-110 based on preliminary clinical trial results.
- Reason for Denial: The FDA was unable to grant the designation because the company failed to provide adequate prevalence estimates and evidence supporting the claim that only moderate to severe TS patients require pharmacological treatment.
- Next Steps: Management intends to respond promptly to provide the missing information.
Outlook, Risks, and Management Commentary
Management believes it can provide adequate data to address the issues raised by the FDA. However, the filing explicitly states there is no assurance that the company will successfully obtain orphan drug designation for Tourette Syndrome. The outcome remains contingent on the company's ability to satisfy the FDA's requirements regarding prevalence and patient population data.
Investor Verification Checklist
- Verify the specific timeline for the company's resubmission of data to the FDA.
- Confirm the current status of the ongoing clinical trials for THX-110 mentioned in the FDA's rationale.
- Review the company's financial statements (Form 20-F) for cash runway, as this filing contains no financial data.
- Monitor for any future FDA correspondence regarding the resubmitted prevalence estimates.